With a highly specialized team of physicians and researchers, we use cutting-edge techniques to develop treatments for patients that have diseases caused by broken genes. We use gene therapy, which replaces those broken genes with normal functional genes, allowing a patient’s own body to produce proteins to treat their illness. A single injection provides long-lasting treatment, leading to a better quality of life for patients worldwide.

The innovative delivery method AGTC uses is the non-toxic adeno-associated virus (AAV), a safe virus that delivers healthy copies of the gene, replacing defective copies.

AAV is an ideal delivery method because:

It is safe, having never been shown to cause disease.

It is effective and provides long-lasting benefit.

Its production is fully scalable and does not require animal-derived products.

It has been approved for use in human clinical trials by U.S. and European regulatory agencies.

AGTC has three ongoing ophthalmology development programs and proof-of-concept data in multiple indications.

X-Linked Retinoschisis

An inherited form of retinal degeneration affecting young males, presenting with poor vision by school age. Visual acuity usually worsens during the teenage years and then can lead to serious complications such as vitreous hemorrhage or retinal detachment during adulthood.


An inherited condition that is associated with visual acuity loss, extreme light sensitivity resulting in daytime blindness, and total loss of color discrimination.

X-Linked Retinitis Pigmentosa

An inherited condition that causes boys to develop night blindness by the time they are ten and progresses to legal blindness by their early forties.

Alpha-1 Antitrypsin Deficiency

One of the most common hereditary disorders in the world and the most commonly known genetic risk factor for emphysema, Alpha-1 can also cause liver disease.

Company Growth (employees)
Alachua, US
Size (employees)
72 (est)+36%
AGTC was founded in 1991 and is headquartered in Alachua, US

AGTC Office Locations

AGTC has an office in Alachua
Alachua, US (HQ)
10 14193 NW 119th Pl
Show all (1)

AGTC Financials and Metrics

AGTC Financials

AGTC's revenue was reported to be $47.4 m in FY, 2016

Revenue (Q3, 2017)

8.4 b

Net income (Q3, 2017)

(821 m)

EBIT (Q3, 2017)

(836 m)

Market capitalization (22-Dec-2017)

65.1 m

Cash (30-Jun-2016)

28.9 m
AGTC's current market capitalization is $65.1 m.
USDFY, 2014FY, 2015FY, 2016


1.1 m2.4 m47.4 m

Revenue growth, %


R&D expense

8.5 m16.5 m38.9 m

General and administrative expense

5.2 m10.4 m10.6 m
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017


11.1 m12.2 m12 m11.8 m10.9 b8.4 b

R&D expense

17 m7.2 m7.9 m5.6 m6 b6.3 b

General and administrative expense

3.2 m2.1 m2.4 m2.8 m

Operating expense total

20.3 m9.3 m10.2 m8.4 m8.8 b9.2 b
USDFY, 2014FY, 2015FY, 2016


8.6 m39.2 m28.9 m

Accounts Receivable

14.1 m56.1 k


1.2 m17.5 m

Current Assets

75.4 m64.1 m102.6 m
USDFY, 2014FY, 2015FY, 2016

Net Income

(15.9 m)(24.3 m)(1.4 m)

Depreciation and Amortization

334 k376 k567 k

Accounts Receivable

(6.8 m)(2.9 m)


(1.2 m)(826 k)
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

(9.1 m)3 m2 m3.6 m2.1 b(821 m)

Accounts Payable

7.6 m817 k1.5 m1.1 m718 k817 k
USDY, 2017


158.3 m
Show all financial metrics

AGTC Operating Metrics

FY, 2015FY, 2016

Patents Licensed

Show all operating metrics

AGTC Market Value History

AGTC's Web-traffic and Trends

AGTC Online and Social Media Presence

AGTC Company Life and Culture

You may also be interested in